Funding Daily Summary
Funding Daily Summary: What Happened on October 22, 2026
AptaDir raises €40 million seed round for fragile X program
Arctic Therapeutics also raised $21.5 million to advance two autoimmune candidates toward clinical testing.
Today in brief
AptaDir Therapeutics raised €40 million to advance its fragile X syndrome program, which aims to reactivate silenced genes.1 Arctic Therapeutics raised $21.5 million to advance two autoimmune drug candidates toward clinical testing.2
Also worth knowing
-
AptaDir is developing RNA-DNA chimeras that block a methylation enzyme at a specific genetic location to reactivate silenced genes. CEO Giovanni Amabile said the financing should fund four years of work, including a Phase I trial he hopes to start in about 18 months.1
-
Arctic said its round was oversubscribed and will support AT-002 and AT-003 as they move toward clinical testing.2